Americana Partners LLC Sells 374 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Americana Partners LLC reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,946 shares of the medical research company’s stock after selling 374 shares during the quarter. Americana Partners LLC’s holdings in Thermo Fisher Scientific were worth $2,735,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Summa Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $418,000. Private Wealth Management Group LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $110,000. Brookstone Capital Management lifted its stake in shares of Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares during the last quarter. Y.D. More Investments Ltd grew its position in Thermo Fisher Scientific by 33.9% during the 4th quarter. Y.D. More Investments Ltd now owns 391 shares of the medical research company’s stock worth $207,000 after acquiring an additional 99 shares during the last quarter. Finally, Artisan Partners Limited Partnership bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $40,335,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.6 %

TMO traded up $3.39 during midday trading on Friday, hitting $615.07. The company had a trading volume of 1,058,979 shares, compared to its average volume of 1,507,778. The company has a market capitalization of $234.96 billion, a price-to-earnings ratio of 39.45, a PEG ratio of 2.82 and a beta of 0.77. The stock’s 50 day moving average price is $578.71 and its 200 day moving average price is $575.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the prior year, the company earned $5.15 earnings per share. The company’s quarterly revenue was down 1.4% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares in the company, valued at $10,747,403.95. The disclosure for this sale can be found here. Insiders sold a total of 33,084 shares of company stock valued at $19,767,092 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent research reports. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. TD Cowen raised their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Robert W. Baird upped their price target on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Finally, Jefferies Financial Group restated a “buy” rating and set a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $630.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.